Attgeno is developing a new treatment for acute high pressure in the lung associated with major cardiac surgery with the aim of reducing the risk of heart failure and fatal outcome.

The development of Supernitro would not have been possible without the entrepreneurship of the Attgeno founders and their associates. The company has within its management, board of directors and scientific advisory associates not just researchers but also individuals with a history of building successful companies emerging from discoveries in nitric oxide and pulmonary hypertension research.